Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2020-12-21 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
유상증자또는주식관련사채등의청약결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Eubiologics regarding the results of a paid-in capital increase (rights offering). It details the subscription results, including the number of shares subscribed, the subscription rate, and the handling of fractional shares. This falls under the category of share issuance and capital changes.
2020-12-21 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing regarding a 'Change in Major Shareholder's Stock Collateral Agreement' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). It details specific financial transactions where the major shareholder (Kim Deok-sang) has pledged shares as collateral for loans. This type of disclosure is a standard regulatory requirement for listed companies in Korea (DART/KRX filings) to inform the market about potential changes in control or financial risk associated with major shareholders. Since it does not fit into specific categories like M&A, Earnings, or Dividends, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2020-12-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose changes in their shareholdings. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2020-12-16 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from a Korean company, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). It includes a 'Correction Report' (정정신고) header, indicating it is an amendment to a previously filed capital increase plan. This document type falls under the category of announcements regarding share issues and capital changes, which is classified as 'SHA' (Share Issue/Capital Change) in the provided schema.
2020-12-15 Korean
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 98% confidence The document is a '증권신고서(지분증권)' (Securities Registration Statement) for a capital increase (rights offering) by Eubiologics. It specifically details the finalization of the issuance price ('발행조건확정') and provides updated financial information regarding the use of proceeds. This is a formal regulatory filing required by the Financial Services Commission (금융위원회) in South Korea for equity offerings. Since it is a formal regulatory document detailing capital structure changes and share issuance, it falls under the 'Regulatory Filings' category.
2020-12-15 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '정정신고(보고)' (Amendment Report) for an '투자설명서' (Investment Prospectus) filed by Eubiologics Co., Ltd. It details the finalization of the offering price for a capital increase (rights offering). This type of document is a formal regulatory filing related to securities issuance and capital structure changes, which falls under the 'Capital/Financing Update' category.
2020-12-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.